Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Jazz Pharmaceuticals

Jazz Pharmaceuticals Stock, a Barchart Favorite, Trends Higher as Trump Renews Cannabis Hopes. Should You Buy JAZZ Here?

Jazz Pharmaceuticals stock pops as President Trump signals renewed urgency to reclassify cannabis as Schedule III drug. Technicals signal further upside ahead in JAZZ shares.

Barchart

Investors Have Been Waiting to Buy the Dip in This Hot Biopharma Stock

Jazz Pharmaceuticals (JAZZ) is a specialty biopharma company focused on neuroscience and oncology. JAZZ exhibits strong technical momentum. Shares are up nearly 50% over the past year. The stock maintains a 100% “Buy” technical opinion from Barchart. Wall Street sentiment is bullish with multiple “Strong Buy” ratings and price targets...

Barchart

Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday

U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Monday.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Small Cap Stocks To Play As The Bantamweights Break Out On Wall Street

The SP 600 Small Cap Index is only up 2.0% year-to-date, but the small-cap trajectory is trending to the upside, with the index returning 5.8% since July.

Benzinga

CBD Drug For Tuberous Sclerosis: Caregivers Continue Epidiolex Treatment Citing Seizure Reduction And Cognitive Improvements

The majority of caregivers of patients with tuberous sclerosis complex (TSC) planned to continue Epidiolex treatment, citing benefits like reduced seizure frequency and improvements in cognition and communication. That's according to data from the BECOME-TSC (BEhavior, COgnition, and More with Epidiolex) caregiver survey, revealed by Jazz Pharmaceuticals plc (NASDAQ: JAZZ).…

Benzinga

Cannabis medications could be eligible for FDA approval under proposed DEA rules

For the first time, cannabis plant would drastically shift federal legal status from narcotic to regulated medication

The Guardian - US

Scientists to investigate whether CBD can treat psychosis

CBD is currently only prescribed on the NHS for a few conditions

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Oxford study to trial cannabis-based medicine as treatment for psychosis

CBD is currently only prescribed for a small number of conditions such as rare, severe epilepsy

The Guardian - UK

Use of cannabis chemical as psychosis treatment being investigated

CBD is currently only prescribed by the NHS for a few conditions such as epilepsy

Wales Online

3 Biotech Stocks to Help Boost Your Portfolio in January

Increased government initiatives and the rising adoption of biotechnology in healthcare and agriculture are likely to enhance the growth of the biotech industry. Hence, fundamentally sound biotech stocks Vertex Pharmaceuticals (VRTX), Biogen (BIIB), and Jazz Pharmaceuticals (JAZZ) might be ideal additions to your portfolio as they look well-positioned to capitalize…

StockNews.com

Jazz Pharmaceuticals Announces Q3 2022 Financial Results, Raises Total Revenue Guidance

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced its financial results late Wednesday for the third quarter of 2022 and raised the mid-point of 2022 total revenue guidance.

Benzinga

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The US Food and Drug Administration (FDA) has accepted for filing Krystal Biotech’s (NASDAQ:KRYS) Biologics License Application (BLA) for its lead candidate B-VEC in the treatment of patients with dystrophic epidermolysis bullosa (DEB). The regulatory agency has granted Priority Review designation and assigned a target actin date of February 17,…

Benzinga

Jazz' Epidiolex, The Only FDA-Approved CBD Drug, Enters Phase 3 Trial Evaluating Its Effects In Patients With Myoclonic-Atonic Seizures

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has initiated a new Phase 3 trial to investigate the efficacy and safety of Epidiolex (cannabidiol), known as Epidyolex in Europe, in children and adolescents with e

Benzinga

Jazz Pharmaceuticals' Late-Stage Multiple Sclerosis Study Misses Primary Endpoint

Jazz Pharmaceuticals (NASDAQ: JAZZ) announced top-line results from the Phase 3 clinical trial investigating nabiximols oromucosal spray (JZP378) on clinical measures of spasticity in individuals with multiple sclerosis (MS).

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

4 Analysts Have This to Say About Jazz Pharmaceuticals

Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings within the last quarter:

Benzinga

What 6 Analyst Ratings Have To Say About Jazz Pharmaceuticals

Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings within the last quarter:

Benzinga

Jazz Pharma Reports Q1 Epidiolex Sales Increased 6% To $157.9M YoY

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) released financial results for the first quarter of 2022.

Benzinga

Jazz Pharmaceuticals: Q1 Earnings Insights

Jazz Pharmaceuticals (NASDAQ:JAZZ) reported its Q1 earnings results on Wednesday, May 4, 2022 at 05:05 PM. Here's what investors need to know about the announcement.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Werewolf Therapeutics Shares Jump On Cancer Product Pact With Jazz Pharma

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has acquired exclusive global development and commercialization rights to Werewolf Therapeutics Inc's (NASDAQ:HOWL) WTX-613. WTX-613 is a differentiated, conditionally-activated interferon-alpha (IFNα) INDUKINE molecule. "We believe WTX-613 has the potential to minimize the toxicity associated with systemic IFNα therapy, preferentially delivering IFNα to tumors, and thereby expanding its clinical utility in treating…

Benzinga

Expert Ratings For Jazz Pharmaceuticals

Over the past 3 months, 4 analysts have published their opinion on Jazz Pharmaceuticals (NASDAQ:JAZZ) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Jazz Pharma Building New State-Of-The-Art Facility For Cannabis-Based Research And Production

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and its subsidiary, GW Pharmaceuticals have begun construction of its new, state-of-the-art manufacturing facility at Kent Science Park (KSP) in Sittingbourne, UK, with an investment of over $100 million.

Benzinga

Jazz Pharma Getting New State-Of-The-Art Facility For Cannabis-Based Research And Production

Benzinga

Jazz Pharmaceuticals's Return On Capital Employed Insights

According to data from Benzinga Pro, during Q4, Jazz Pharmaceuticals's (NASDAQ:JAZZ) reported sales totaled $896.73 million. Despite a 33.09% increase in earnings, the company posted a loss of $35.35 million.

Benzinga

Expert Ratings For Jazz Pharmaceuticals

Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings within the last quarter:

Benzinga

Why Jazz Pharmaceuticals Shares Are Rising

Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) shares are trading higher by 10.5% at $151.00 after the company reported better-than-expected fourth-quarter EPS and sales results.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

European Medicines Agency

76 stories

Valneva

72 stories

Vertex Pharmaceuticals Incorporated

65 stories

Travelzoo

45 stories

Jazz Pharmaceuticals plc

44 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.